Related Experiment Videos

[Supraventricular paroxysmal tachycardia as a pediatric cardiologic emergency]

Insights

Digitalis effectively treats supraventricular paroxysmal tachycardia in infants and children, leading to rapid rhythm conversion and preventing relapses. This study highlights digitalis as a reliable and accessible treatment option with no reported mortality.

Area of Science:

  • Pediatric Cardiology
  • Pharmacology

Context:

  • Supraventricular paroxysmal tachycardia (SVPT) is a significant arrhythmia in pediatric populations.
  • Management of infant and childhood SVPT requires effective and safe therapeutic interventions.

Purpose:

  • To evaluate the efficacy and safety of digitalis in treating pediatric supraventricular paroxysmal tachycardia.
  • To assess the role of digitalis in preventing recurrence and managing potential heart failure in affected children.

Summary:

  • Seven pediatric cases of electrocardiogram-confirmed supraventricular paroxysmal tachycardia, predominantly in infants, were treated with digitalis.
  • Digitalis facilitated short-term conversion to sinus rhythm and was continued for relapse and heart failure prevention.
  • The treatment demonstrated a favorable safety profile with no mortality observed.

Impact:

  • Digitalis is recommended as a selective, readily available, and reliable medication for pediatric SVPT.
  • The findings support the established literature on digitalis efficacy in managing pediatric arrhythmias.
  • Successful management of SVPT in pediatric patients can prevent significant morbidity and mortality.

Related Concept Videos